journal
Journals American Journal of Clinical D...

American Journal of Clinical Dermatology

https://read.qxmd.com/read/38438782/small-molecule-inhibitors-and-biologics-for-palmoplantar-psoriasis-and-palmoplantar-pustulosis-a-systematic-review-and-network-meta-analysis
#21
JOURNAL ARTICLE
I-Hsin Huang, Po-Chien Wu, Hsien-Yi Chiu, Yu-Huei Huang
BACKGROUND: The comparative efficacy of biologics and small-molecule inhibitors in treating palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) remains uncertain. OBJECTIVE: The aim was to perform a systematic review and network meta-analysis (NMA) to compare the efficacy of biologics and small-molecule inhibitors for the treatment of PP and PPP. METHODS: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched for eligible studies from inception to May 13, 2023...
March 4, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38305944/autoimmune-and-cutaneous-inflammatory-comorbidities-in-adult-onset-morphea-in-the-all-of-us-research-program
#22
LETTER
Jill T Shah, William Mark Richardson, Lavanya Mittal, Emily Hejazi, Daniel R Mazori, Alisa N Femia
No abstract text is available yet for this article.
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38265746/treatment-of-psoriasis-patients-with-latent-tuberculosis-using-il-17-and-il-23-inhibitors-a-retrospective-multinational-multicentre-study
#23
MULTICENTER STUDY
Tiago Torres, Andrea Chiricozzi, Luis Puig, Ana Maria Lé, Angelo Valerio Marzano, Paolo Dapavo, Esteban Dauden, Jόse-Manuel Carrascosa, Elizabeth Lazaridou, Gleison Duarte, André V E Carvalho, Ricardo Romiti, Natalia Rompoti, Laetitia Teixeira, Miguel Abreu, Elena Ippoliti, Carlo Alberto Maronese, Mar Llamas-Velasco, Eva Vilarrasa, Elena Del Alcázar, Athina-Ioanna Daponte, Marina Papoutsaki, Andrea Carugno, Francesco Bellinato, Paolo Gisondi
BACKGROUND: Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. Available evidence from clinical trials and real-world studies suggests that IL-17 and IL-23 inhibitors do not increase the risk of tuberculosis reactivation...
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38263353/integrated-safety-analysis-of-ritlecitinib-an-oral-jak3-tec-family-kinase-inhibitor-for-the-treatment-of-alopecia-areata-from-the-allegro-clinical-trial-program
#24
JOURNAL ARTICLE
Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Natasha A Mesinkovska, Carle Paul, Yankun Gong, Susan D Anway, Helen Tran, Robert Wolk, Samuel H Zwillich, Alexandre Lejeune
BACKGROUND: The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged ≥ 12 years with alopecia areata (AA). OBJECTIVE: The objective of this study was to evaluate the safety of ritlecitinib in an integrated analysis of four studies in AA. METHODS: Two cohorts were analyzed: a placebo-controlled and an all-exposure cohort...
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38252188/the-skin-microbiome-and-its-significance-for-dermatologists
#25
JOURNAL ARTICLE
Cleo Whiting, Sara Abdel Azim, Adam Friedman
The skin is a physical and immunological barrier to the external environment. Its large surface area is colonized by diverse communities of microorganisms, including bacteria, viruses, fungi, and Demodex species mites. These microorganisms and their genetic material together create the skin microbiome. Physiologic and anatomic properties of skin sites create biogeographical habitats (dry, moist, and sebaceous) where distinct microbiota communities reside. Although, in general, the composition of these habitats is maintained from person to person, the skin microbiome of an individual also has unique microbial features...
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38217568/mucocutaneous-manifestations-of-recreational-drug-use
#26
REVIEW
Carolina V Alexander-Savino, Ginat W Mirowski, Donna A Culton
Recreational drug use is increasingly common in the dermatology patient population and is often associated with both general and specific mucocutaneous manifestations. Signs of substance use disorder may include changes to general appearance, skin, and mucosal findings associated with particular routes of drug administration (injection, insufflation, or inhalation) or findings specific to a particular drug. In this review article, we provide an overview of the mucocutaneous manifestations of illicit drug use including cocaine, methamphetamine, heroin, hallucinogens, marijuana, and common adulterants to facilitate the identification and improved care of these patients with the goal being to connect this patient population with appropriate resources for treatment...
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38216802/targeted-systemic-therapies-for-adults-with-atopic-dermatitis-selecting-from-biologics-and-jak-inhibitors
#27
REVIEW
Richard W Kim, Megan Lam, Katrina Abuabara, Eric L Simpson, Aaron M Drucker
Therapeutic options for people with moderate or severe atopic dermatitis refractory to topical therapy have rapidly expanded in recent years. These new targeted immunomodulatory agents-biologics and Janus kinase (JAK) inhibitors-have each demonstrated high levels of efficacy and acceptable safety in mostly placebo-controlled clinical trials for atopic dermatitis, but there is no universally applicable algorithm to help choose between them for a given patient. Hence, patients and physicians should utilize shared decision making, discussing efficacy, safety, mode of delivery, monitoring, costs, speed of onset, and other factors to reach individualized treatment decisions...
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38159214/pressure-and-skin-a-review-of-disease-entities-driven-or-influenced-by-mechanical-pressure
#28
REVIEW
Wei-Chen Chien, Tsen-Fang Tsai
Skin perceives and reacts to external mechanical forces to create resistance against the external environment. Excessive or inappropriate stimuli of pressure may lead to cellular alterations of the skin and the development of both benign and malignant skin disorders. We conducted a comprehensive literature review to delve into the pressure-induced and aggravated skin disorders and their underlying pressure-related mechanisms. Dysregulated mechanical responses of the skin give rise to local inflammation, ischemia, necrosis, proliferation, hyperkeratosis, impaired regeneration, atrophy, or other injurious reactions, resulting in various disease entities...
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38159213/pityriasis-rubra-pilaris-an-updated-review-of-clinical-presentation-etiopathogenesis-and-treatment-options
#29
REVIEW
Tejas P Joshi, Madeleine Duvic
Pityriasis rubra pilaris (PRP) is a rare papulosquamous reaction pattern with a significant impact on quality of life. Type I PRP is the most common PRP variant, presenting as erythematous papules emerging in a follicular distribution and later coalescing into plaques with characteristic islands of sparing; histologically, an alternating pattern of orthokeratosis and parakeratosis is considered the hallmark of PRP (checkerboard hyperkeratosis). Other PRP variants (types II-V) differ in their age of onset and clinical presentation...
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38087156/recent-advances-in-treatment-of-systemic-sclerosis-and-morphea
#30
REVIEW
Noelle Teske, Nicole Fett
Systemic sclerosis (SSc) and morphea are autoimmune sclerosing diseases that cause significant morbidity, and in the case of SSc, mortality. The pathogenesis of both SSc and morphea share vascular dysfunction, auto-reactive T cells and Th2-associated cytokines, such as interleukin 4, and overproduction of transforming growth factor beta (TGFβ). TGFβ stimulates fibroblast collagen and extra-cellular matrix production. Although morphea and SSc have similar pathogenic pathways and histological findings, they are distinct diseases...
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38366030/the-impact-of-dermatologic-adverse-events-on-the-quality-of-life-of-oncology-patients-a-review-of-the-literature
#31
REVIEW
Annika Belzer, Jolanta J Pach, Kailyn Valido, Jonathan S Leventhal
Dermatologic adverse events resulting from oncologic therapy are common and negatively impact patients' quality of life. Dermatologic adverse events include toxicity of the skin, oral mucosa, nails, and hair and are seen with cytotoxic chemotherapy, targeted therapy, immunotherapy, and radiation therapy, with distinct patterns of dermatologic adverse events by drug class. Here, we review the literature on the impact of dermatologic adverse events on quality of life. Studies on quality of life in patients with cancer have relied on scales such as the Dermatologic Life Quality Index and Skindex to demonstrate the association between dermatologic adverse events and declining quality of life...
February 16, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38340153/correction-to-ox40-in-the-pathogenesis-of-atopic-dermatitis-a-new-therapeutic-target
#32
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard B Warren, Andreas Wollenberg, Emma Guttman-Yassky
No abstract text is available yet for this article.
February 10, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38337127/autoimmune-autoinflammatory-disease-and-cutaneous-malignancy-associations-with-hidradenitis-suppurativa-a-cross-sectional-study
#33
JOURNAL ARTICLE
Hilliard T Brydges, Ogechukwu C Onuh, Rebecca Friedman, Joy Barrett, Rebecca A Betensky, Catherine P Lu, Avrom S Caplan, Afsaneh Alavi, Ernest S Chiu
BACKGROUND: Hidradenitis suppurativa (HS) is a debilitating cutaneous disease characterized by severe painful inflammatory nodules/abscesses. At present, data regarding the epidemiology and pathophysiology of this disease are limited. OBJECTIVE: To define the prevalence and comorbidity associations of HS. METHODS: This was a cross-sectional study of EPICTM Cosmos© examining over 180 million US patients. Prevalences were calculated by demographic and odds ratios (OR) and identified comorbidity correlations...
February 9, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38329690/therapeutic-strategies-in-braf-v600-wild-type-cutaneous-melanoma
#34
REVIEW
Alexandra Haugh, Adil I Daud
There have been many recent advances in melanoma therapy. While 50% of melanomas have a BRAF mutation and are a target for BRAF inhibitors, the remaining 50% are BRAF wild-type. Immune checkpoint inhibitors targeting PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and lymphocyte activated gene-3 (Lag-3) are all approved for the treatment of patients with advanced BRAF wild-type melanoma; however, treatment of this patient population following initial immune checkpoint blockade is a current therapeutic challenge given the lack of other efficacious options...
February 8, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38243107/real-world-use-of-ruxolitinib-cream-safety-analysis-at-1-year
#35
JOURNAL ARTICLE
Wilson Hu, Michele Thornton, Robert A Livingston
BACKGROUND: Ruxolitinib cream is the first topical Janus kinase (JAK) inhibitor approved in the United States (US) for the treatment of mild to moderate atopic dermatitis and nonsegmental vitiligo. A postmarketing study with oral tofacitinib, approved for rheumatoid arthritis, triggered class warnings for JAK inhibitors, including risk of serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. Because ruxolitinib cream is indicated for inflammatory conditions, it is subject to the same warnings as oral JAK inhibitors in the US...
January 19, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38236520/ox40-in-the-pathogenesis-of-atopic-dermatitis-a-new-therapeutic-target
#36
REVIEW
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard B Warren, Andreas Wollenberg, Emma Guttman-Yassky
Atopic dermatitis (AD) is a chronic, heterogeneous, inflammatory disease characterized by skin lesions, pruritus, and pain. Patients with moderate-to-severe AD experience chronic symptoms, intensified by unpredictable flares, and often have comorbidities and secondary complications, which can result in significant clinical burden that impacts the patient's overall quality of life. The complex interplay of immune dysregulation and skin barrier disruption drives AD pathogenesis, of which T-cell-dependent inflammation plays a critical role in patients with AD...
January 18, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38191979/acknowledgement-to-referees
#37
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
January 8, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38079107/treat-to-target-in-atopic-dermatitis
#38
REVIEW
Christian Vestergaard, Catalina Skovsgaard, Claus Johansen, Mette Deleuran, Jacob P Thyssen
Atopic dermatitis is one of the most common inflammatory skin diseases among children and adults. Over the last 5 years, the armamentarium for the treatment of this disease, with both topical and systemic drugs, has increased. Treat-to-target is basically the concept where a treatment goal and a time frame for that goal is set at initiation of a new treatment, and if the goals are not achieved in time, treatment will be adjusted. In clinical trials, treatment targets are based on scoring systems for disease severity as recommended by the Harmonizing Outcome Measure for Eczema (HOME) initiative, with the primary endpoint being a reduction of at least 75% of the baseline Eczema Area and Severity Index (EASI) score (EASI-75)...
January 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38060175/author-correction-efficacy-and-safety-of-apremilast-for-the-treatment-of-japanese-patients-with-palmoplantar-pustulosis-results-from-a-phase-2-randomized-placebo-controlled-study
#39
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Shigetoshi Sano, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Masafumi Yaguchi, Natsuka Uehara, Takahiro Handa, Masayuki Tanaka, Wendy Zhang, Maria Paris, Masamoto Murakami
No abstract text is available yet for this article.
January 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38042767/photodynamic-therapy-in-treating-a-subset-of-basal-cell-carcinoma-strengths-shortcomings-comparisons-with-surgical-modalities-and-potential-role-as-adjunctive-therapy
#40
REVIEW
Maggie Chen, Albert Zhou, Amor Khachemoune
Basal cell carcinoma (BCC) is the most common skin cancer, for which there are multiple treatment options, including the gold standard Mohs micrographic surgery (MMS), surgical excision, electrodesiccation and curettage, radiation therapy, cryosurgery, and photodynamic therapy (PDT). While PDT is currently approved for treating actinic keratosis, it has been used off-label to treat BCC patients who may not tolerate surgery or other treatment modalities. We present a review of the efficacy of these modalities and describe important considerations that affect the usage of PDT and MMS...
January 2024: American Journal of Clinical Dermatology
journal
journal
34795
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.